Skip to main content
Search result for "Solr search content"
Search Result for "*:*"
Clinical Trial

Tucatinib, Palbociclib and Letrozole in Metastatic Hormone Receptor Positive and HER2-positive Breast Cancer

This is a noninterventional study in an adult population of men and women with a diagnosis of MF or PV. The study will enroll patients with a diagnosis of PV or MF. Basic demographic information and disease history will be collected. Participants will also be subjected to a physical examination. Viable frozen mononuclear cells (MNCs) will be collected from participants via blood draw (patients with MF) or therapeutic phlebotomy (patients with PV). In addition to samples collected from patients with PV and MF, banked MNCs from peripheral blood or bone marrow may also be included in the study. CD34+ cells will be isolated from MNCs from patients with PV and MF and the banked samples. Cryopreserved CD34+ cells obtained from the bone marrow of healthy participants will be purchased from a third party. All CD34+ cell specimens (from patients, banked specimens, and healthy participants) will undergo epigenetic and gene expression analyses. For each disease state (MF and PV), the epigenomes of patients and healthy participants will be compared with each other in order to identify potential novel gene control targets.

Clinical Trial

VX15/2503 in Treating Younger Patients With Recurrent, Relapsed, or Refractory Solid Tumors

This phase I/II trial studies the side effects and best dose of anti-SEMA4D monoclonal antibody VX15/2503 (VX15/2503) and to see how well it works in treating younger patients with solid tumors that have come back after treatment, or do not respond to treatment. Monoclonal antibodies, such as VX15/2503, may interfere with the ability of tumor cells to grow and spread.

Clinical Trial

Breast/Evaluation of Cryotherapy and TRPA1 Receptors in Chemotherapy Induced Neuropathy

This is a therapeutic study investigating the use of cryotherapy in the prevention of chemotherapy-induced peripheral neuropathy (CIPN) and associated nail toxicities. The therapeutic intervention will involve patients wearing an Elasto-Gel cold glove and sock on their non-dominant hand and foot. The dominant side will not have the glove and sock applied and will act as an internal control. The patients will wear the glove and sock during each infusion of taxane chemotherapy. Infusion therapy, assessments and patient questionnaires will take place in the Cancer Treatment and Research Center (CTRC) and the Electromyography Studies (EMG) will be performed at the Medical Arts and Research Center (MARC). The primary aim is to demonstrate if cryotherapy is a safe and effective intervention in preventing peripheral neuropathy and nail toxicity in patients receiving taxane chemotherapy. The secondary aim is evaluating the relation of CIPN with gene expression of TRPA1, TRPV1 and TRPM8.

Clinical Trial

Reduced Craniospinal Radiation Therapy and Chemotherapy in Treating Younger Patients With Newly Diagnosed WNT-Driven Medulloblastoma

This phase II trial studies how well reduced doses of radiation therapy to the brain and spine (craniospinal) and chemotherapy work in treating patients with newly diagnosed type of brain tumor called WNT)/Wingless (WNT)-driven medulloblastoma. Recent studies using chemotherapy and radiation therapy have been shown to be effective in treating patients with WNT-driven medulloblastoma. However, there is a concern about the late side effects of treatment, such as learning difficulties, lower amounts of hormones, or other problems in performing daily activities. Radiotherapy uses high-energy radiation from x-rays to kill cancer cells and shrink tumors. Drugs used in chemotherapy, such as cisplatin, vincristine sulfate, cyclophosphamide and lomustine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving reduced craniospinal radiation therapy and chemotherapy may kill tumor cells and may also reduce the late side effects of treatment.

Clinical Trial

Selumetinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating MAPK Pathway Mutations (A Pediatric MATCH Treatment Trial)

To determine the objective response rate (ORR; complete response + partial response) in pediatric patients treated with selumetinib (AZD6244 hydrogen sulfate) with advanced solid tumors (including CNS tumors), non-Hodgkin lymphomas or histiocytic disorder that harbor activating genetic alterations in MAPK pathway.

Clinical Trial

Cisplatin and Combination Chemotherapy in Treating Children and Young Adults With Hepatoblastoma or Liver Cancer After Surgery

This partially randomized phase II/III trial studies how well cisplatin and combination chemotherapy works in treating children and young adults with hepatoblastoma or liver cancer after surgery. Drugs used in chemotherapy, such as cisplatin, doxorubicin, fluorouracil, vincristine sulfate, carboplatin, etoposide, irinotecan, sorafenib, gemcitabine and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving combination chemotherapy after surgery may kill more tumor cells.